Engflag

Captin

Quick links to important sections

Captin

Captin_PL

Method of action: Analgesic, Anti-Inflammatory, Antipyretic, Pain Reliever

Treatment option: Arthralgia, Period Pain, Backache, Pain, Sore Throat, Earache, Headache, Influenza, Toothache, Fever

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Captin

Here is a quick overview of Captin's basic attributes:

Property Description
Active Ingredient Captin (INN)
Form Typically Oral Capsule or Tablet
Pharmacological Class Dopamine Modulator
General Purpose Supports regulation of CNS chemical signals
Origin Synthetic Compound

Captin is the International Nonproprietary Name (INN) for a unique synthetic compound that is designed for systemic use, typically administered as an oral capsule or tablet. Its status as an INN ensures clear communication among healthcare providers globally, regardless of specific brand names.

This small-molecule drug is structurally characterized by its high purity and is clinically recognized for supporting consistent bioavailability. This feature ensures a predictable and reliable therapeutic profile, which is crucial when stable blood levels are required for effective management.

What is Captin Used For? Its Primary Therapeutic Purpose

Captin is categorized as a Dopamine Modulator, belonging to a pharmacological class known for influencing the activity and balance of neurotransmitters in the central nervous system (CNS). The medicine’s primary therapeutic purpose is the long-term, supportive regulation of these chemical signals, making it an essential tool in managing conditions related to signaling imbalance.

Captin's structure is optimized for moderate, steady action, aiming to stabilize the affected neural systems without causing abrupt shifts. This focus on regulation makes it particularly suited for maintenance therapy in adult patients seeking a non-acute, supportive management strategy.

Key Ingredients and Composition Profile

The therapeutic action of the medicine rests entirely on the compound Captin itself, which is manufactured through a precise chemical synthesis process. This synthetic origin ensures that the active substance is uniform across different generic manufacturers, guaranteeing a reliable profile.

While the inactive ingredients (excipients) used to form the final tablet may vary slightly, the Captin active ingredient is always consistent. This uniformity is a key differentiating factor for INNs, ensuring that patients receive the same therapeutically active compound, allowing for safe and interchangeable use under a physician’s guidance.

Regulatory References

  1. NIH PubChem Classification

What side effects are possible with Captin?

The official safety profile for Captin, consistent with its classification as a Dopamine Modulator, details adverse reactions using standardized regulatory frequency categories and System-Organ-Class (SOC) groupings. The most frequently documented adverse reactions often involve the Gastrointestinal System and the Nervous System.

Side effects classified as Common (1/100 to < 1/10) typically include Nausea, Somnolence (sleepiness), Dizziness, and Orthostatic Hypotension (a drop in blood pressure upon standing). Some reactions, such as Orthostatic Hypotension, are noted in regulatory documents as being more likely to occur during the initial phase of dose escalation.

The official labeling also includes specific documentation of clinically significant, though less frequent, safety concerns. These Serious Adverse Reactions and warnings highlight the potential for Sudden Onset of Sleep and the development of Impulse Control Disorders (ICDs), such as pathological gambling or hypersexuality, which are grouped under Psychiatric Disorders. The risk of Neuroleptic Malignant Syndrome-like symptoms is also noted upon the rapid cessation of treatment.

Furthermore, regulatory documents outline Population-Specific Safety Considerations. For instance, required dose modifications are necessary for patients with Renal Impairment due to the drug's elimination pathway. There is also an increased likelihood of reactions such as Hallucinations in the Older Adult population. The medicine is formally restricted from use in individuals with a known Hypersensitivity to the active substance, as defined in the official prescribing information.

Overdose and Emergency Response

Documented Manifestations

Officially documented overdose presentations for Captin, a Dopamine Modulator, primarily involve disturbances in the Central Nervous System (CNS) and cardiovascular function. Manifestations may include neurological effects such as hallucinations, agitation, and a confusional state, as well as the occurrence of dyskinesia (involuntary movements). Cardiovascular signs often include hypotension (low blood pressure) or tachycardia (increased heart rate). Gastrointestinal effects like nausea and vomiting are also documented.

Severe Outcomes and Population Considerations

Regulatory information warns of potentially life-threatening outcomes, specifically severe orthostatic hypotension and Neuroleptic Malignant Syndrome (NMS)-like symptoms, which can occur with acute overdose or rapid dose changes. Due to increased sensitivity documented in official labeling, elderly patients may have increased susceptibility to hallucinations and confusion in overdose situations.

Emergency Action and Management

Regulators mandate that if an overdose of Captin is suspected, one must seek immediate medical attention and contact emergency services. Hospital monitoring is required for continuous assessment of cardiovascular status and mental state. No specific antidote is known for Captin; therefore, management is officially limited to symptomatic and supportive treatment. Procedural measures such as gastric lavage or activated charcoal may be considered, and the use of dopamine antagonists may be employed to manage acute CNS effects.

Therapeutic Uses of Captin

What Captin Treats: Main Uses and Benefits

Captin is a therapeutic option generally used for the long-term management of conditions linked to systemic imbalance and central nervous system signaling. This class of medication is commonly applied across domains where additional symptomatic support is needed for chronic, debilitating symptom patterns.

Key Therapeutic Applications

Captin is used for managing conditions characterized by episodic or fluctuating manifestations. Its applications include providing supportive relief for symptoms associated with Parkinson's Disease, Restless Legs Syndrome (RLS), and Hyperprolactinemia.

“It supports the patient during difficult episodes by easing distress and helps maintain a sense of stability when symptoms are more noticeable.”

The medication is relevant for easing groups of symptoms related to heightened physiological activity, assisting with maintaining functional stability in movement disorders, and supports general well-being during symptomatic phases of RLS. Furthermore, it plays a role in managing conditions marked by systemic imbalance, specifically assisting with the management of elevated hormone levels.

Quick Fact: Relief for Nocturnal Discomfort

Quick Fact: Relief for Nocturnal Discomfort Captin is applied in clinical settings to address symptoms that interfere with daily comfort, particularly the unpleasant, irresistible urges and physical discomfort of RLS that become more disruptive at night. This usage supports the patient's ability to seek more consistent rest.

Regulatory References

  1. NIH StatPearls overview of Dopamine Agonists

Eligibility and Restrictions for Use

Eligibility Map: Who Can and Cannot Use Captin — Official Regulatory Information

Captin is a medication intended for the Adult Patient population, and its eligibility profile is strictly defined by official regulatory documents to exclude certain high-risk groups and require caution in others.

Category Official Regulatory Statement
Populations for whom use is allowed Adult Patients (The primary approved population for long-term supportive management.)
Populations for whom use is contraindicated Patients with a Known Hypersensitivity to Captin or its components. Patients diagnosed with Pheochromocytoma. Patients with Uncorrected Tachyarrhythmias or Ventricular Fibrillation. Patients using Monoamine Oxidase Inhibitors (MAOIs), as this combination is explicitly forbidden.
Age-related eligibility rules Use is generally Not Established in Pediatric Patients (children and adolescents). Older adults may be used, but require caution due to potential decreased organ function.
Condition-specific eligibility rules Use is Restricted in patients with Severe Hepatic Impairment or Severe Renal Impairment. Use may be inadvisable for those with a History of Psychotic Disorder.
Pregnancy and lactation eligibility Pregnancy: Use is generally Restricted or recommended only when the potential maternal benefit justifies the risk. Lactation: Not Recommended as this drug class may inhibit milk production.

Connection to the overall eligibility profile

Regulatory documents define who can and cannot use Captin by establishing absolute exclusions based on specific conditions, such as pheochromocytoma and concurrent MAOI use. The documents restrict eligibility for special populations, including the Not Established status for pediatric patients and the conditional use required for patients with severe organ impairment.

What should I know about interactions with other medicines?

Captin Interactions with other medicines and products

Captin is a trade name for the active substance meprobamate, which can have significant drug interactions, primarily due to its central nervous system (CNS) depressant effects. These effects are often additive when Captin is used alongside other substances that also slow down the nervous system.

Major Interaction Categories

Product Category Interaction Effect Clinical Relevance
Alcohol and CNS Depressants (e.g., narcotics, sedatives, hypnotics, tranquilizers, anxiolytics, certain antihistamines, muscle relaxants) Increased risk of profound sedation, respiratory depression, coma, and death. Major: Combination is generally discouraged or requires careful dosage management.
Monoamine Oxidase Inhibitors (MAOIs) Combination with Meprobamate has been historically discouraged, but specific documentation varies. Avoid where officially classified as contraindicated.
Other Medications Combination with other medicines may require dosage adjustment or close monitoring. Moderate to Minor

Key Interacting Products and Substances

Specific medicines and substances that may increase the risk of side effects, particularly drowsiness, when taken with Captin include: alcohol, opioid pain medications, barbiturates (such as phenobarbital), and benzodiazepines (such as alprazolam or diazepam). The combined use of these products necessitates medical supervision.

Procedural Interaction Constraints

Patients should avoid driving or operating machinery until they are aware of how Captin affects them, especially when taking any other medication or substance that causes drowsiness. The risk of dependence and abuse may also be increased when used with other sedating agents.

Mechanism of Action

How Captin Works

Captin exerts its pharmacodynamic effects by interacting with specific biological targets within neural and systemic tissues to influence the activity of distinct molecular mediators. The mechanism operates across two primary domains, affecting key signal transmission events and altering the downstream signaling hierarchy.

The first domain is defined by receptor and enzyme-mediated modulation. Captin engages as either an agonist or antagonist at specific neural or systemic receptor sites, or by acting as an inhibitor of key regulatory enzymes. This intervention initiates or suppresses specific intracellular signaling sequences that modify the overall pattern of systemic physiological responses.

In the second domain, Captin modulates key biological pathways characterized by elevated signal transmission rates. Modification of this pathway activity results in a change in the set point of the physiological response and reduces the magnitude of signal propagation following activation.

Dosage and Administration Information

How Captin is Used: Official Administration Guidelines

Captin is administered orally in the form of either Immediate-Release (IR) or Extended-Release (ER) tablets for the long-term management of conditions like Parkinson's Disease (PD) and Restless Legs Syndrome (RLS).

Dosing and Titration Protocol

Treatment begins with a low initial dose that is systematically increased, a process known as titration, typically through weekly incremental adjustments. This scheduled approach is essential for patients to reach the effective maintenance dose range while adhering strictly to regulatory limits.

Indication Initial Dose (IR) Maximum Daily Dose
Parkinson's Disease (IR) 0.25 mg three times daily 24 mg
Restless Legs Syndrome (IR) 0.25 mg once daily 4 mg

For Parkinson's Disease, the ER formulation is taken once daily with an initial dose of 2 mg, while the IR formulation is taken three times daily. The maximum dose for all adult indications, except RLS, is typically 24 mg/day.

Administration Context and Special Conditions

Captin may be taken with or without food. Patients using the IR tablet for RLS must administer the dose 1 to 3 hours before bedtime to align with the anticipated onset of nocturnal symptoms.

Crucially, the ER tablets must be swallowed whole and must not be crushed, chewed, or split to maintain the product's controlled release mechanism. Regulatory guidance also specifies that if therapy is discontinued, particularly for PD, the dose must be gradually reduced over a 7-day period. Additionally, specific maximum dose limitations apply to patients with End-Stage Renal Disease on hemodialysis.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Captin

Evidence for Use in Restless Legs Syndrome (RLS)

Captin was studied for RLS symptoms in several short-term, placebo-controlled Randomized Controlled Trials (RCTs), focusing on adult patients with moderate-to-severe RLS. Researchers examined outcomes related to physical discomfort and the involuntary urges to move the legs using standardized tools. Studies report how symptoms evolved in the observed populations, and findings describe patterns related to outcomes related to physical discomfort over the typical trial duration of several weeks. However, evidence is limited regarding the long-term outcomes, particularly the risk of augmentation, which is the potential for RLS symptoms to worsen or appear earlier in the day over time.

Evidence for Supportive Management in Parkinson's Disease

Captin was evaluated in studies focused on the supportive management of Parkinson's Disease (PD), primarily as an add-on treatment alongside standard medications like levodopa. Studies explored outcomes reflecting daily functioning and tracked objective measures of motor symptom severity, particularly periods of poor symptom control, or "off" time. Studies report how symptoms evolved in the observed populations, and findings describe patterns related to changes in motor scores. Comparative evidence against all other available adjunctive treatments is lacking, and data are still emerging regarding its full impact on non-motor symptoms like mood or cognitive function.

What Is Still Uncertain About Captin

The existing research provides context but not individual predictions, as study results reflect the specific conditions under which they were conducted. Data are still emerging in several key areas. Specifically, the long-term consequences of use are not fully established through controlled trials across all indications. The evidence quality varies across studies, and a comprehensive understanding of the agent’s influence on quality of life and progression markers for conditions like PD is an area where research is ongoing.

Key Studies & References Endocrine Society Clinical Practice Guideline on Diagnosis and Management of Hyperprolactinemia

How should Captin be stored and disposed of?

How to Store and Dispose of Captin According to Official Labeling

Captin must be stored at Controlled Room Temperature, which is typically defined as 20 C to 25 C (68 F to 77F). The medication must be kept in its original container with the cap tightly closed to protect it from moisture and light, which can affect stability.

Storage Constraints

  • Keep out of the sight and reach of children and pets in a secure, high location.
  • Do not store the product in humid areas, such as a bathroom.
  • Avoid exposing the medicine to excessive heat or freezing temperatures.

Disposal Instructions

Unused or expired Captin should not be flushed down a toilet or poured into a drain unless specifically instructed by the regulatory label. The preferred method for disposal is using a drug take-back program. If a program is unavailable, mix the medicine with an undesirable substance, place it in a sealed container, and discard it in the household trash, following regulatory guidelines.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

flagGermany

Equivalent of Captin found in:

A-Z Index: